SafeBoosC-IIIv - Does Cerebral Oximetry Monitoring Affect Renal Outcomes
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-28
SponsorSt. John's Research Institute
About this trial
Cerebral oximetry monitoring allows clinicians to optimize blood flow to the brain and oxygenation using the SafeBoosC treatment guideline. The guideline's interventions aims to stabilize blood pressure and oxygen levels.
As low blood pressure is a risk factor for the development of kidney injury, normalizing blood pressure may decrease the incidence of kidney injury in new-borns who are on ventilator.
Eligibility criteria
Qualifiers
> 28 weeks of gestation Invasively ventilated
Disqualifiers
major anomalies
Trial design
Treatments tested in this trial
- Intervention Arm- Cerebral Oximetry + Treatment Guideline
Treatment groups
1,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
St. John's Research Institute
Lead sponsor
Rigshospitalet, Denmark
Collaborator
Source ClinicalTrials.gov